Logo

Roche's Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

Share this

Roche's Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

Shots:

  • The approval is based on two P-III studies: The SAkuraStar & SAkuraSky studies involves assessing Enspryng as monothx.  and in combination with IST vs PBO in 95 & 83 NMOSD patients who are AQP4 seropositive aged 18-74yrs. & 12-74yrs. respectively
  • SAkuraStar & SAkuraSky results: 74% & 79% reduction in the risk of relapses respectively
  • Enspryng (SC- q4w) is a mAb targeting IL-6R treatment. Additionally- Canada is the first country to receive health authority approval for Enspryng- offering a new treatment option for NMOSD  

­ Ref: Newswire Canada | Image: Roche

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions